Top In Vitro Diagnostic Solution Companies - 2020
LifeSign: Changing the Face of Healthcare with Point of Care Testing Solutions

Top 10 In Vitro Diagnostic Solution Companies - 2020

With a continual rise in chronic and infectious diseases and rising health awareness, the healthcare landscape has seen a rapid surge in in-vitro diagnostic (IVD) technologies. The market is now being flooded with advanced medical devices and testing kits for performing tests on tissue, urine, and blood, with the aim of early detection of diseases, monitoring drug intake, and keeping a check on the medical conditions.

Recently, the field of in-vitro diagnostics has also witnessed a surge in R&D activities in order to kick-start the decade with novel discoveries. The beginning of 2020 has seen the market segmentation of in-vitro in more specific segments like molecular diagnostics, immunoassay, and hematology with molecular diagnostics are suspected to grow at a higher rate.

In the case of non-infectious diseases, IVD is increasingly being used for prenatal and neonatal screening, tissue typing for transplantation, hereditary disease screening, and detecting cancer markers in the blood. Alongside, the domain is exploring medical possibilities in for few other infectious diseases like HIV and Hepatitis, among the many others. However, factors like inadequate reimbursement and stringent government policies on the manufacture of in-vitro products have limited the growth of the market.

Nonetheless, with in-vitro diagnosis growing relatively faster this year, the healthcare domain is witnessing a new era of expansion and innovation, which can help them grow and scale globally, perform better, and gain a strategic edge over its competitors. At this juncture, there is a wide variety of in-vitro solutions providers entering the domain with a set of advanced and integrated offerings. To help medtech companies strengthen their medical services and simultaneously enable growth in the industry, MedTech Outlook has compiled a list of the top 10 in-vitro diagnostic technology solution providers. The list comprises prominent organizations in the industry that are striving to solve healthcare challenges by implementing the current trends in the space. Besides, the magazine also comprises insights from thought leaders in the sector on the industry trends, best practices, recent innovations, and their advice for the aspiring CXOs.

We present to you MedTech Outlook’s, “Top 10 In Vitro Diagnostic Technology Solution Providers – 2020.”

    Top In Vitro Diagnostic Solution Companies

    eNano Health
    eNano Health develops a range of disruptive saliva-based solutions for self-health management and quick screening of multiple diseases based on its patented platform technology
    GMSbiotech
    GMSbiotech provides a flexible platform to deliver improved DNA and Protein-based diagnostic tests. The company utilizes unique microarray technology, which is simple and less expensive compared to other technologies available in the market. GMSbiotech focuses on HLA typing for organ transplantation, Pre- and Post-transplantation antibody screening as well as transfusion medicine. The company offers easy-to-use and cost-effective products under its brand name GMSbio-Chip including EZMatchTM, EZScreenTM, and RicimerTM GMSbiotech Analysis software. Through its disruptive raw sample genotyping technology, GMSbiotech also mitigates the challenge of DNA purification that limits the workflow in terms of time and cost in genotyping by reducing the steps in the analysis.
    LifeSign
    A medical diagnostic company delivering high quality rapid point of care testing solutions. The firm’s extensive line of innovative testing products is used worldwide for the detection of medical conditions and illnesses that include infectious disease, women’s health, drugs of abuse, and cardiac markers. LifeSign offers a range of in vitro rapid qualitative tests that detect infectious diseases such as flu, strep, and mono directly from nasal swab/nasopharyngeal swab, throat swab, and blood respectively. All of LifeSign’s solutions are developed and manufactured under ISO, FDA cGMP, and CE mark guidelines, and marketed and supported with the highest of quality standards by LifeSign's team of sales, technical, and customer service professionals
    Beckman Coulter
    Beckman Coulter is committed to advancing healthcare for every person by applying the power of science, technology, and the passion and creativity of our teams to enhance the diagnostic laboratory’s role in improving healthcare outcomes. Our diagnostic systems are used in complex biomedical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. Beckman Coulter offers a unique combination of people, processes and solutions designed to elevate the performance of clinical laboratories and healthcare networks. We do this by accelerating care with a menu that matters, bringing the benefit of automation to all, delivering greater insights through clinical informatics and unlocking hidden value through performance partnership. An operating company of Danaher Corporation since 2011, Beckman Coulter is headquartered in Brea, Calif., and has more than 11,000 global associates working diligently to make the world a healthier place
    Co-Diagnostics
    Co-Diagnostics, Inc. is a molecular diagnostics company with unique, patented Polymerase Chain Reaction (“PCR”) testing technology. A Utah corporation headquartered in Salt Lake City, Utah, we commercialize our innovative patented and patent-pending technology through sales, development and licensing, to quickly develop molecular diagnostics that are more cost-efficient and perform better than traditional technologies of the past
    Critical Diagnostics
    Critical Diagnostics helps physicians optimize patient care in cardiovascular diseases, such as heart failure. Our high sensitivity Presage® ST2 Assay measures the level of soluble ST2 in blood, identifying patients at increased risk of adverse events and mortality. ST2 has been evaluated in multiple clinical studies, now spanning more than 31,000 subjects
    DiaCarta
    DiaCarta, a translational genomics and precision molecular diagnostics company, was established in 2011 to provide highly sensitive and advanced technologies that will improve the way molecular diagnostics and translational genomics impact healthcare treatment plans and the well-being of individuals around the world. With over 80 global patents, DiaCarta offers a range of products and services, from single-gene cancer mutation detection qPCR assays, colorectal cancer mutation detection panels, radiation therapy toxicity monitoring cfDNA test to its targeted NGS panels
    NanoDx
    NanoDx Inc. is a privately held medical device company developing novel and rapid point-of-care technologies for the objective diagnosis and management of concussion and other traumatic brain injury (TBI). The company’s lead product, the NanoDx™ blood test, delivers biologically based results shown to confirm a concussion accurately in less than 90 seconds. BioDirection’s platform utilizes a patented bio-nanowire technology with the potential for use in a range of applications in point-of-care diagnostics
    Nova Biomedical
    Nova Biomedical is a company dedicated to using advanced technology to develop better blood testing analyzers for medical use. These products are called in vitro diagnostic devices (IVD). We use some of the same advanced technology to provide the biotechnology industry with innovative instruments for cell culture monitoring. Nova is the largest privately owned IVD company in the U.S. and the third largest in the world, with over 1,200 employees globally. Our eight percent compounded annual growth over nearly a decade is more than double the IVD market growth, making Nova one the fastest growing IVD companies in the world
    Randox
    The Randox ethos of improving healthcare, which drove our Managing Director Dr Peter FitzGerald to start the company in the 1980s, continues today. Up to 25% of our turnover is reinvested in research and development to enable our scientists to work on the development of pioneering tests for a range of common illnesses such as cancer, cardiovascular disease and Alzheimer’s disease. Randox is dedicated to improving health worldwide by developing pioneering health technologies for early and accurate diagnosis

In Vitro Diagnostics Info

Q1
What Do Top In Vitro Diagnostics Solutions Do?
Top In Vitro Diagnostics Solutions support testing performed on samples such as blood, tissue, urine and swabs outside the body, usually in laboratories, hospitals or point-of-care settings. These solutions may involve instruments, reagents, assay platforms, sample preparation tools, workflow software or connected reporting systems. For healthcare organizations, the category sits close to clinical decision-making: test accuracy, turnaround time, sample integrity and result interpretation can affect diagnosis, treatment selection, infection control and patient follow-up.
Q2
Why Do Top In Vitro Diagnostics Solutions Matter Now?
It's critical for top In Vitro Diagnostics solutions because health teams must detect disease earlier, increase test volume and decrease turnaround time from collection to clinical decision, disease monitoring, molecular testing, distributed care, antimicrobial resistance, public health preparedness and other market dynamics will drive demand. Additionally, issues such as labor shortages, reimbursement challenges and quality expectations continue to stress labs and are factors in assessing in Vitro Diagnostics solutions based on ability to integrate into current capacity.
Q3
How Should Healthcare Decision-Makers Evaluate In Vitro Diagnostics Providers?
Decision-makers have to look at the width and breadth of the test menu, analytical capability, regulatory clearance status, throughput, maintenance requirements, reliability of reagents and interface with the LIMS. Also need to consider training, particularly if it's a platform that will be deployed across several sites or near the patient. Good vendors make validation, quality control, service response and documentation easier for laboratory directors, clinicians and those doing purchasing; a poor fit often shows up much later.
Q4
What Value Can In Vitro Diagnostics Solutions Create for Care Delivery?
Top in vitro diagnostics solutions create the most value when they help clinicians move faster from sample collection to clear clinical decisions. Rapid infectious disease testing can help care teams respond sooner and make timely isolation decisions. More accurate molecular assays can guide treatment selection with greater confidence. Improved sample tracking can reduce lost specimens, paperwork errors and delays caused by manual reconciliation. The impact goes beyond speed alone. Reliable diagnostics can help avoid unnecessary follow-up visits, support earlier treatment and give clinicians clearer direction when symptoms are difficult to interpret. For patients, that often means less waiting, less uncertainty and a clearer understanding of what comes next.
Q5
How Are Technology and Expertise Changing This Category?
Automation, digital connectivity and AI-assisted interpretation are reshaping diagnostics, but experienced laboratory teams still play a critical role. In real lab environments, platforms must consistently manage differences in specimen quality, calibration needs, error alerts and routine quality checks without disrupting workflow. Software can make routing, result review and disease surveillance more efficient, but clinicians and laboratory leaders still need systems they can understand, trust and confidently govern. The strongest in vitro diagnostics providers recognize that testing is not just about delivering an instrument or assay. They combine scientific expertise, reliable engineering, data management and responsive service support to help laboratories operate smoothly under everyday clinical pressures.
Q6
What Should Healthcare Organizations Prioritize When Comparing Options?
Healthcare organizations comparing Top In Vitro Diagnostics Solutions should prioritize clinical reliability, implementation fit, lifecycle cost, service coverage and reporting integration. A lower upfront price may be less attractive if reagent availability is uncertain or maintenance causes repeated downtime. Decision-makers should also look at scalability across departments, cybersecurity expectations for connected systems and the provider’s ability to support audits, staff training and software updates. The strongest choice is usually the one that protects result quality while reducing friction for the laboratory team.